ClinicalTrials.gg
CompletedNCT00092196Updated May 5, 2017

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

A Phase 3 interventional study of MK0869, aprepitant / Duration of Treatment: 3 days in Nausea, Vomiting and Breast Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Dec 2002, registered Sep 2004).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
820
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Nausea by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Nausea · Merck & Co., Inc.

Enrollment
2nd of 10
820 · median 464
Started
2002
with 1 other
Phase 3
Only one
of the 11
Registered
2nd of 11
by date

Among the 11 studies in Nausea by Merck & Co., Inc, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2002, is the only one in phase 3, and was the 2nd registered.

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

Browse Nausea studies →

Open to participants now

None of the 11 studies in Nausea by Merck & Co., Inc is open now. The open studies under Nausea, anywhere →

Who these studies take

Of the 51 Nausea studies recruiting now, 21 (41%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Nausea by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.

03

Conditions studied

  • Nausea
  • Vomiting
  • Breast Neoplasms

Keywords

  • Chemotherapy-Induced Nausea and Vomiting
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy.
  • Patient must have completed participation in the main study for this protocol.

Exclusion criteria

Exclusion Criteria:

  • Patient has a central nervous system .
  • Patient will receive radiation to the abdomen or pelvis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
820 participants (actual)

Interventions

  • DrugMK0869, aprepitant / Duration of Treatment: 3 days
06

What researchers measure

Primary outcomes

  1. Safety and tolerability

Secondary outcomes

  1. Assessment of adverse experiences using the National Cancer Institute (NCI) criteria

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F; Aprepitant Moderately Emetogenic Chemotherapy Study Group. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005 Oct 1;104(7):1548-55. doi: 10.1002/cncr.21343. Erratum In: Cancer. 2006 Apr 1;106(7):1641. PubMed 16104039 ↗
  • Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005 Apr 20;23(12):2822-30. doi: 10.1200/JCO.2005.09.050. Erratum In: J Clin Oncol. 2005 Aug 20;23(24):5851. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. PubMed 15837996 ↗
  • Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev. 2013 Feb;39(1):113-7. doi: 10.1016/j.ctrv.2012.09.002. Epub 2012 Oct 11. PubMed 23062719 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2002 to primary completion in Dec 2004, 24 months.

Of 43 phase 3 interventional studies under Nausea, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2004
First posted
Sep 24, 2004
StartActual
Dec 1, 2002
Primary completionActual
Dec 1, 2004
CompletionActual
Dec 1, 2004
Last update
May 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00092196
Responsible party
Sponsor
First posted
Sep 24, 2004
Start date
Dec 1, 2002
Primary completion
Dec 1, 2004
Completion
Dec 1, 2004
Last update
May 5, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion